This report focuses on the global Cancer Immunotherapy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Cancer Immunotherapy development in United States, Europe and China.
In 2017, the global Cancer Immunotherapy market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of during 2018-2025.
The key players covered in this study
Amgen, Inc.
AstraZeneca
F. Hoffmann La Roche Ltd.
Bayer AG
Bristol-Myers Squibb Company
Eli Lilly and Company
Merck and Co., Inc.
Novartis AG
Pfizer, Inc.
Market segment by Type, the product can be split into
Monoclonal Antibodies
Immunomodulators
Oncolytic Viral Therapies and Cancer Vaccines
Market segment by Application, split into
Lung Cancer
Breast Cancer
Colorectal Cancer
Melanoma
Prostate Cancer
Head and Neck Cancer
Ovarian Cancer
Pancreatic Cancer
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Cancer Immunotherapy status, future forecast, growth opportunity, key market and key players.
To present the Cancer Immunotherapy development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Cancer Immunotherapy are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025
For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Cancer Immunotherapy Market, By Product
7.1. Cancer Immunotherapy Market, By Product, 2021-2028
7.1.1. Monoclonal Antibodies
7.1.1.1. Market Revenue and Forecast (2016-2028)
7.1.2. Immunomodulators
7.1.2.1. Market Revenue and Forecast (2016-2028)
7.1.3. Oncolytic Viral Therapies and Cancer Vaccines
7.1.3.1. Market Revenue and Forecast (2016-2028)
Chapter 8. Global Cancer Immunotherapy Market, By Cancer Type
8.1. Cancer Immunotherapy Market, By Cancer Type, 2021-2028
8.1.1. Lung Cancer
8.1.1.1. Market Revenue and Forecast (2016-2028)
8.1.2. Breast Cancer
8.1.2.1. Market Revenue and Forecast (2016-2028)
8.1.3. Colorectal Cancer
8.1.3.1. Market Revenue and Forecast (2016-2028)
8.1.4. Melanoma
8.1.4.1. Market Revenue and Forecast (2016-2028)
8.1.5. Prostate Cancer
8.1.5.1. Market Revenue and Forecast (2016-2028)
8.1.6. Head and Neck Cancer
8.1.6.1. Market Revenue and Forecast (2016-2028)
8.1.7. Ovarian Cancer
8.1.7.1. Market Revenue and Forecast (2016-2028)
8.1.8. Pancreatic Cancer
8.1.8.1. Market Revenue and Forecast (2016-2028)
Chapter 9. Global Cancer Immunotherapy Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, By Product (2016-2028)
9.1.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.1.3. U.S.
9.1.3.1. Market Revenue and Forecast, By Product (2016-2028)
9.1.3.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.1.4. Rest of North America
9.1.4.1. Market Revenue and Forecast, By Product (2016-2028)
9.1.4.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.2. Europe
9.2.1. Market Revenue and Forecast, By Product (2016-2028)
9.2.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.2.3. UK
9.2.3.1. Market Revenue and Forecast, By Product (2016-2028)
9.2.3.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.2.4. Germany
9.2.4.1. Market Revenue and Forecast, By Product (2016-2028)
9.2.4.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.2.5. France
9.2.5.1. Market Revenue and Forecast, By Product (2016-2028)
9.2.5.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.2.6. Rest of Europe
9.2.6.1. Market Revenue and Forecast, By Product (2016-2028)
9.2.6.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.3. APAC
9.3.1. Market Revenue and Forecast, By Product (2016-2028)
9.3.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.3.3. India
9.3.3.1. Market Revenue and Forecast, By Product (2016-2028)
9.3.3.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.3.4. China
9.3.4.1. Market Revenue and Forecast, By Product (2016-2028)
9.3.4.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.3.5. Japan
9.3.5.1. Market Revenue and Forecast, By Product (2016-2028)
9.3.5.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.3.6. Rest of APAC
9.3.6.1. Market Revenue and Forecast, By Product (2016-2028)
9.3.6.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.4. MEA
9.4.1. Market Revenue and Forecast, By Product (2016-2028)
9.4.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.4.3. GCC
9.4.3.1. Market Revenue and Forecast, By Product (2016-2028)
9.4.3.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.4.4. North Africa
9.4.4.1. Market Revenue and Forecast, By Product (2016-2028)
9.4.4.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.4.5. South Africa
9.4.5.1. Market Revenue and Forecast, By Product (2016-2028)
9.4.5.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.4.6. Rest of MEA
9.4.6.1. Market Revenue and Forecast, By Product (2016-2028)
9.4.6.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.5. Latin America
9.5.1. Market Revenue and Forecast, By Product (2016-2028)
9.5.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.5.3. Brazil
9.5.3.1. Market Revenue and Forecast, By Product (2016-2028)
9.5.3.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
9.5.4. Rest of LATAM
9.5.4.1. Market Revenue and Forecast, By Product (2016-2028)
9.5.4.2. Market Revenue and Forecast, By Cancer Type (2016-2028)
Chapter 10. Company Profiles
10.1. Amgen Inc.
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. AstraZeneca
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. F. Hoffman La Roche
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Bayer AG
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. Bristol-Myers Squibb
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. Eli Lilly and Co.
10.6.1. Company Overview
10.6.2. Product Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. Merck and Co.
10.7.1. Company Overview
10.7.2. Product Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. Novartis
10.8.1. Company Overview
10.8.2. Product Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9. Pfizer
10.9.1. Company Overview
10.9.2. Product Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
Chapter 11. Research Methodology
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
Chapter 12. Appendix
12.1. About Us
Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers